Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
Novartis Pharmaceuticals
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- ORION-8
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 3275
- sponsor
- Novartis Pharmaceuticals
- conditions
- ASCVD; Elevated Cholesterol; Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia
- interventions
- DRUG: Inclisiran Sodium
- start date
- 2019-04-16
- start date type
- ACTUAL
- primary completion date
- 2023-02-13
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT03814187
- Published
- Jan 23, 2019
- Updated
- Mar 6, 2024
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT03814187
- Categories
- ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials